We are live on ! Find out more

2,823 hedge funds and large institutions have $92B invested in Pfizer in 2026 Q2 according to their latest regulatory filings, with 154 funds opening new positions, 1,159 increasing their positions, 1,212 reducing their positions, and 235 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.8% more ownership

Funds ownership: 66.15%66.95% (+0.8%)

4% less repeat investments, than reductions

Existing positions increased: 1,159 | Existing positions reduced: 1,212

10% less call options, than puts

Call options by funds: $2.36B | Put options by funds: $2.62B

4% less funds holding

Funds holding: 2,9552,823 (-132)

13% less capital invested

Capital invested by funds: $106B → $92B (-$13.6B)

34% less first-time investments, than exits

New positions opened: 154 | Existing positions closed: 235

55% less funds holding in top 10

Funds holding in top 10: 4721 (-26)

Holders
2,823
Holders Change
-132
Holders Change %
-4.47%
% of All Funds
33.99%
Holding in Top 10
21
Holding in Top 10 Change
-26
Holding in Top 10 Change %
-55.32%
% of All Funds
0.25%
New
154
Increased
1,159
Reduced
1,212
Closed
235
Calls
$2.36B
Puts
$2.62B
Net Calls
-$257M
Net Calls Change
-$657M

PFE Hedge Fund Activity: Q2 2026 in Review

2,823 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q2 2026, worth a combined $92B — down 13% from $106B a quarter earlier.

Sellers outnumbered buyers: 235 funds closed out of PFE and 154 opened new positions — a net loss of 81 holders — while 1,212 trimmed existing stakes and 1,159 added.

The largest buyer was BlackRock, adding an estimated $822M. The largest seller was Wellington Management Group, cutting an estimated $578M.

  • 2,823 institutional investors held Pfizer (PFE) as of Q2 2026, down from 2,955 in Q1 2026.
  • Funds reported $92B of Pfizer stock for Q2 2026, down 13% quarter-over-quarter.
  • 154 funds opened new Pfizer positions in Q2 2026 and 235 closed out, a net change of -81 holders.
  • The largest Pfizer buyer in Q2 2026 was BlackRock, an estimated $822M added.
  • The largest Pfizer seller in Q2 2026 was Wellington Management Group, an estimated $578M sold.

Based on aggregated 13F filings for Q2 2026.